Comparison between Glenmark Life Sciences IPO and Nuvoco Vistas IPO.
Glenmark Life Sciences IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Nuvoco Vistas IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Glenmark Life Sciences IPO is up to ₹1,513.60 Cr whereas the issue size of the Nuvoco Vistas IPO is up to ₹5,000.00 Cr. The final issue price of Glenmark Life Sciences IPO is ₹720.00 per share and of Nuvoco Vistas IPO is ₹570.00 per share.
| Glenmark Life Sciences IPO | Nuvoco Vistas IPO | |
|---|---|---|
| Face Value | ₹2 per share | ₹10 per share |
| Issue Price (Lower) | ₹695.00 per share | ₹560.00 per share |
| Issue Price (Upper) | ₹720.00 per share | ₹570.00 per share |
| Issue Price (Final) | ₹720.00 per share | ₹570.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ||
| Market Lot Size | 20 shares | 26 shares |
| Fresh Issue Size | 1,47,22,222 shares | 2,63,15,789 shares |
| Fresh Issue Size (Amount) | up to ₹1,060.00 Cr | up to ₹1,500.00 Cr |
| OFS Issue Size | 63,00,000 shares | 6,14,03,508 shares |
| OFS Issue Size (Amount) | up to ₹453.60 Cr | up to ₹3,500.00 Cr |
| Issue Size Total | 2,10,22,222 shares | 8,77,19,297 shares |
| Issue Size Total (Amount) | up to ₹1,513.60 Cr | up to ₹5,000.00 Cr |
Glenmark Life Sciences IPO opens on Jul 27, 2021, while Nuvoco Vistas IPO opens on Aug 09, 2021. The closing date of Glenmark Life Sciences IPO and Nuvoco Vistas IPO is Jul 29, 2021, and Aug 11, 2021, respectively.
| Glenmark Life Sciences IPO | Nuvoco Vistas IPO | |
|---|---|---|
| Anchor Bid Date | Jul 26, 2021 | Aug 06, 2021 |
| Issue Open | Jul 27, 2021 | Aug 09, 2021 |
| Issue Close | Jul 29, 2021 | Aug 11, 2021 |
| Basis Of Allotment (Tentative) | Aug 03, 2021 | Aug 17, 2021 |
| Initiation of Refunds (Tentative) | Aug 04, 2021 | Aug 18, 2021 |
| Credit of Share (Tentative) | Aug 05, 2021 | Aug 20, 2021 |
| Listing date (Tentative) | Aug 06, 2021 | Aug 23, 2021 |
| Anchor Lockin End date 1 | Sep 02, 2021 | Sep 16, 2021 |
| Anchor Lockin End date 2 | Nov 01, 2021 | Nov 15, 2021 |
Glenmark Life Sciences IPO P/E ratio is , as compared to Nuvoco Vistas IPO P/E ratio of .
| Glenmark Life Sciences IPO | Nuvoco Vistas IPO | |||||
|---|---|---|---|---|---|---|
| Financials | Company Financials ()
| Company Financials ()
| ||||
| Promoter Shareholding (Pre-Issue) | 100 | 95.24 | ||||
| Promoter Shareholding (Post-Issue) | 82.84 | 71.03 | ||||
| P/E Ratio | ||||||
| Market Cap | ₹8821.96 Cr. | ₹20357.90 Cr. | ||||
| ROE | ||||||
| ROCE | ||||||
| Debt/Equity | ||||||
| EPS | ||||||
| RoNW |
In the Glenmark Life Sciences IPO Retail Individual Investors (RII) are offered 73,57,778 shares while in Nuvoco Vistas IPO retail investors are offered 73,57,778 shares. Qualified Institutional Buyers (QIB) are offered 42,04,450 shares in Glenmark Life Sciences IPO and 1,75,43,860 shares in Nuvoco Vistas IPO.
| Glenmark Life Sciences IPO | Nuvoco Vistas IPO | |
|---|---|---|
| Anchor Investor Reservation | 63,06,660 shares | 2,63,15,788 shares |
| Market Maker Reservation | ||
| QIB | 42,04,450 shares | 1,75,43,860 shares |
| NII | 31,53,334 shares | 1,31,57,895 shares |
| RII | 73,57,778 shares | 3,07,01,754 shares |
| Employee | ||
| Others | ||
| Total | 2,10,22,222 shares | 8,77,19,297 shares |
Glenmark Life Sciences IPO subscribed 44.17x in total, whereas Nuvoco Vistas IPO subscribed 1.71x.
| Glenmark Life Sciences IPO | Nuvoco Vistas IPO | |
|---|---|---|
| QIB (times) | 36.97x | 4.23x |
| NII (times) | 122.54x | 0.66x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 14.63x | 0.73x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 44.17x | 1.71x |
